UBS Group’s Frontline FRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q3
– Sell
-3,000
Closed -$37K – 8479
2015
Q2
$37K Hold
3,000
– – ﹤0.01% 6276
2015
Q1
$34K Buy
+3,000
New +$41.8K ﹤0.01% 6422
2014
Q3
– Sell
-300
Closed -$4K – 10478
2014
Q2
$4K Buy
300
+140
+88% +$2.13K ﹤0.01% 9656
2014
Q1
$3K Sell
160
-2,060
-93% -$42.8K ﹤0.01% 9834
2013
Q4
$42K Sell
2,220
-10,980
-83% -$151K ﹤0.01% 7180
2013
Q3
$175K Buy
13,200
+1,560
+13% +$19.6K ﹤0.01% 5347
2013
Q2
$103K Hold
11,640
– – ﹤0.01% 5870

Other funds holding FRO

UBS Group's FRO Position: Q3 2026 in Review

UBS Group reduced its Frontline (FRO) stake by 27% in Q3 2026, selling an estimated $27.1M and leaving 1,754,187 shares worth $86.4M. The position accounts for 0.01% of the portfolio, ranked #1211.

UBS Group first reported a position in FRO in Q2 2013 and has held it in 54 quarters since. The position peaked at $87.6M in Q1 2026. 296 funds tracked by Wall St. Rank hold FRO as of Q3 2026.

  • UBS Group held 1,754,187 shares of Frontline worth $86.4M as of Q3 2026.
  • UBS Group sold 636,086 Frontline shares in Q3 2026, an estimated $27.1M.
  • Frontline made up 0.01% of UBS Group's portfolio in Q3 2026, its #1211 holding.
  • UBS Group first reported a position in Frontline in Q2 2013 and has held it in 54 quarters since.
  • UBS Group's Frontline position peaked at $87.6M in Q1 2026.
  • 296 funds tracked by Wall St. Rank held Frontline as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.